Vancomycin removal during high-volume peritoneal dialysis in acute kidney injury patients

dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade de São Paulo (USP)
dc.contributorUniversity of San Diego
dc.date.accessioned2019-10-06T15:36:33Z
dc.date.accessioned2022-12-19T18:31:09Z
dc.date.available2019-10-06T15:36:33Z
dc.date.available2022-12-19T18:31:09Z
dc.date.created2019-10-06T15:36:33Z
dc.date.issued2019-03-01
dc.identifierPeritoneal Dialysis International, v. 39, n. 2, p. 183-187, 2019.
dc.identifier1718-4304
dc.identifier0896-8608
dc.identifierhttp://hdl.handle.net/11449/187453
dc.identifier10.3747/pdi.2018.00092
dc.identifier2-s2.0-85062832421
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5368491
dc.description.abstractStudies on vancomycin pharmacokinetics in acute kidney injury (AKI) patients on high-volume peritoneal dialysis (HVPD) are lacking. We studied the pharmacokinetics of intravenous (IV) vancomycin in AKI patients treated by HVPD who received a prescribed single IV dose of vancomycin (15 – 20 mg/kg total body weight) to determine the extent of vancomycin removal and to establish vancomycin dosing guidelines for the empirical treatment of AKI patients receiving HVPD. The application of 18 mg/kg vancomycin every 48 – 72 hours in AKI patients undergoing HVPD was required to maintain therapeutic concentrations.
dc.languageeng
dc.relationPeritoneal Dialysis International
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectAKI
dc.subjectsepsis
dc.titleVancomycin removal during high-volume peritoneal dialysis in acute kidney injury patients
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución